Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

About WAPE
U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands | WAPE

Back All news

NewsPR Newswire

Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands

Nov 5, 2026, 08:00 ET · Published

View source

Article summary

October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a contract development and...

An excerpt from the original article.

Related companies

Scinai Immunotherapeutics Ltd. American Depositary SharesSCNIView stock

Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands

Article summary

Related companies

Analyzed by WAPE AI.

Comments —